Home > Keywords > Thématique > Science

Science

Articles

  • TIDES Europe, Nov. 11-13, 2020 - 100% Virtual
    12 November 2020, by Elodie DORMES

    Dr Guillaume JACQUOT will share a presentation on “TfR-targeting VHH Nanobodies for Extra-hepatic Delivery of Oligonucleotides” a good opportunity for Vect-Horus to present its last results.
    A live Q&A session will also give the opportunity to ask questions on last trends and highlights in Oligonucleotide & Peptide Therapeutics field to expert panelists.
    TIDE is the Europe’s #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate new (…)

  • Blood Brain Barrier Summit delivered digitally
    10 August 2020, by Elodie DORMES

    Vect-Horus will assist to the Blood Brain Barrier Summit, delivered digitally from August 31 to September 2nd, 2020

  • Festival of Biologics 2019 in BASEL
    31 October 2019, by Elodie DORMES

    Meet with Pascaline LECORCHE during the Festival of Biologics 2019, 15 – 17 October 2019 _ Basel Switzerland and discuss on « Design of peptide-based vectors for targeted delivery ».

  • Vect-Horus will present at Delivery of Macromolecules, June 8, 2022
    30 May 2022, by Elodie DORMES

    Guillaume JACQUOT, Head of Intracellular Trafficking & Translational Research, will give a talk on this occasion.

  • Vect-Horus will join the ARVO Annual Meeting
    17 April 2024, by Emmanuelle BETTENDORF

    We’re excited to present a poster on our targeted drug delivery technology at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, taking place in Seattle, WA, USA from May 5-9, 2024.
    The poster is titled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”.
    It will be available at ARVO on May 7, 2024, from 3:30pm to 5:15pm PDT Posterboard Number 3992 - B0036 and Session (…)

  • Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
    22 April 2024, by Emmanuelle BETTENDORF

    Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26 (MDPI).
    The paper, entitled “LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo”, outlines a study which showed how peptides (…)

  • Vect-Horus announces the expansion of its Scientific Advisory Board
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS is a French biotechnology company that designs and develops peptide-vectors to facilitate the delivery of drugs or imaging agents into the brain and other organs, and in particular in tumours. VECT-HORUS announces the expansion of its Scientific Advisory Board (SAB). Chaired by Prof. Jean-Michel SCHERRMANN, this Scientific Council is composed of several personalities and opinion leaders of international renown. (…)

  • LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma
    30 September 2021, by Elodie DORMES

    Vect-Horus is proud to be part of the research in PDAC with its theranostic agents to first improve PDAC diagnosis, response monitoring or recurrence detection in operated patients and also treat them.
    Cedric malicet, Oncology Department Manager, is pleased to inform you of the recent publication of the article “ LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma “ in Communications Biology.

  • Vect-Horus and its academic partners describe the chemical optimisation of one of its lead peptides (Malcor et al., 2012, J Med Chem)
    28 January 2019, by Jonathan NOWAK

    and publish a review article on CNS drug delivery (Vlieghe and Khrestchatisky, 2012, Med Res Rev).

  • Our latest research article is now available on bioRxiv and medRxiv
    11 July 2025, by Emmanuelle BETTENDORF

    In this study, we explored the identification and optimization of cross-species reactive VHHs (single-domain antibodies from camelids) targeting the transferrin receptor 1 (TfR1) — a promising strategy for delivering therapeutics across the blood-brain barrier.
    We focused on two candidates, C5 and B8, which bind TfR1 in rodents, non-human primates, and humans. These VHHs show potential as molecular shuttles for transporting imaging or therapeutic agents across species — paving the way for (…)